Table 2 Final criteria for prostate cancer patient selection for AS agreed by Delphi panel
Criteria for recommending active surveillance as a treatment option for patients with localised prostate cancer |
|---|
The following patient factors should be taken into consideration in the decision whether to recommend active surveillance to a patient as a treatment option for prostate cancer:  Medical co-morbidities  Life expectancy  Suitability to undergo radical treatment for prostate cancer  Treatment preferences |
The results of the following tests should be considered in making a decision whether to recommend active surveillance (as a minimum):  Prostate Specific Antigen (PSA)  PSA density  Multiparametric MRI (mpMRI)  Prostate biopsy (with a minimum of 12 cores from a systematic approach ± 2–4 targeted cores from an MRI visible lesion) |
Patients meeting all of the following criteria can be recommended active surveillance as a treatment option. Patients meeting five of the following criteria could also be considered for active surveillance:  PSA less than or equal to 10 ng/mL  PSA density less than or equal to 0.15 ng/mL2  Clinical stage less than or equal to T1c  PIRADS score less than 3  Gleason score 3 + 3/Gleason Grade Group of 1  No family history of prostate cancer |
Patients meeting the following criteria should not be recommended active surveillance as a treatment option:  Gleason score 4 + 3/Gleason Grade Group ≥ 3  Genetic and genomic testing (such as Prostarix or SNP profiles) should not be used to inform decisions about active surveillance |